Metabolic activity via


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
22 Jul 2022
Historique:
received: 23 08 2021
accepted: 05 07 2022
entrez: 22 7 2022
pubmed: 23 7 2022
medline: 27 7 2022
Statut: epublish

Résumé

Identification of microsatellite instability high (MSI-H) colorectal cancer (CRC) is crucial for screening patients most likely to benefit from immunotherapy. We aim to investigate whether the metabolic characteristics is related to MSI status and can be used to predict the MSI-H CRC. A retrospective analysis was conducted on 420 CRC patients who were identified via [ Of 420 colorectal cancers, 44 exhibited a high incidence of MSI. Both MTV and TLG were significantly higher in MSI-H group compared with the MSS group (P = 0.004 and P = 0.010, respectively). Logistic regression analysis indicated that CRC with MSI-H were related to younger age (P = 0.013), primary lesion located at right hemi-colon (P < 0.001) and larger MTV on PET/CT imaging (P = 0.019). MTV more than 32.19 of colorectal cancer was linked to the presence of MSI (P = 0.019). Tumor metabolic burden were higher in MSI-H CRC which may be useful for predicting the MSI status of CRC patient and thus aid in determination of immunotherapy for patients with CRC.

Identifiants

pubmed: 35869469
doi: 10.1186/s12885-022-09871-z
pii: 10.1186/s12885-022-09871-z
pmc: PMC9306059
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

808

Subventions

Organisme : Zhejiang Province Public Welfare Technology Application Research Project
ID : LGF22H180013
Organisme : National Natural Science Foundation of China
ID : 82071957
Organisme : Beijing Hospitals Authority Clinical Medicine Development of Special Funding Support
ID : XMLX202120

Informations de copyright

© 2022. The Author(s).

Références

Eur J Cancer. 2018 Sep;101:181-190
pubmed: 30077123
N Engl J Med. 2003 Mar 6;348(10):919-32
pubmed: 12621137
Genome Med. 2017 May 24;9(1):45
pubmed: 28539127
Nat Rev Clin Oncol. 2020 Jan;17(1):11-32
pubmed: 31289352
Gastroenterology. 2007 Jul;133(1):48-56
pubmed: 17631130
Front Immunol. 2021 Aug 26;12:724464
pubmed: 34512653
Scand J Gastroenterol. 2004 Feb;39(2):138-44
pubmed: 15000275
N Engl J Med. 2003 Jul 17;349(3):247-57
pubmed: 12867608
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Am J Surg Pathol. 2003 Nov;27(11):1407-17
pubmed: 14576473
Expert Rev Anticancer Ther. 2016 May;16(5):557-71
pubmed: 27010906
Lancet Oncol. 2010 Aug;11(8):753-62
pubmed: 20619739
Cancer Med. 2019 Aug;8(10):4699-4708
pubmed: 31270941
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
Cancer Biol Med. 2016 Mar;13(1):120-35
pubmed: 27144067
J Natl Compr Canc Netw. 2017 Mar;15(3):401-410
pubmed: 28275038
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
Cancers (Basel). 2019 Oct 15;11(10):
pubmed: 31618962
J Natl Cancer Inst. 2019 Nov 1;111(11):1131-1141
pubmed: 31322663
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2310-2325
pubmed: 28815334
J Clin Oncol. 2015 Dec 10;33(35):4176-87
pubmed: 26527776
Gastroenterology. 2004 Feb;126(2):394-401
pubmed: 14762775
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
J Exp Med. 2014 May 5;211(5):781-90
pubmed: 24778419
Mod Pathol. 2015 Jan;28 Suppl 1:S109-13
pubmed: 25560596
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
J Natl Cancer Inst. 2011 Jun 8;103(11):863-75
pubmed: 21597022
Am J Surg Pathol. 2009 Jan;33(1):126-33
pubmed: 18830122
Radiologe. 2019 Sep;59(9):812-819
pubmed: 31428810
Abdom Radiol (NY). 2020 Feb;45(2):312-321
pubmed: 31111196
Nucl Med Mol Imaging. 2018 Feb;52(1):5-15
pubmed: 29391907
Acta Biomed. 2018 Dec 17;89(9-S):97-101
pubmed: 30561401
Cancer Sci. 2020 Jun;111(6):1969-1978
pubmed: 32302443
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Cancer Sci. 2020 Aug;111(8):3032-3044
pubmed: 32449240
J Nucl Med. 2019 Nov;60(11):1560-1568
pubmed: 30877175
Cancer Treat Rev. 2016 Dec;51:19-26
pubmed: 27838401
Gastric Cancer. 2013 Apr;16(2):185-92
pubmed: 22692466
N Engl J Med. 2014 Oct 23;371(17):1609-18
pubmed: 25337750
Eur J Nucl Med Mol Imaging. 2021 Sep;48(10):3250-3259
pubmed: 33630146
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2301-2312
pubmed: 32206839

Auteurs

Jinling Song (J)

Department of Nuclear Medicine, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, 310022, China.

Zhongwu Li (Z)

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Lujing Yang (L)

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Maomao Wei (M)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Zhi Yang (Z)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China.

Xuejuan Wang (X)

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), NMPA Key Laboratory for Research and Evaluation of Radiopharmaceuticals (National Medical Products Administration), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, Beijing, 100142, China. xuejuan_wang@hotmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH